Core Viewpoint - Sarepta Therapeutics' shares dropped nearly 30% due to the failure of two approved drugs in a key trial and a weak forecast for its top-selling gene therapy, raising concerns about the company's portfolio strength [1] Group 1: Trial Results and Drug Effectiveness - Sarepta was testing therapies Amondys 45 and Vyondys 53 in a trial aimed at confirming their effectiveness for treating Duchenne muscular dystrophy [2] - The trial results will not affect the drugs' market availability, and the company plans to meet with the U.S. drug regulator to discuss converting the drugs' accelerated approvals into full approvals [3] Group 2: Market Reaction and Analyst Opinions - Analysts express skepticism about the future of Vyondys 53 and Amondys 45, reflecting concerns from investors regarding the stock's reaction [4] - The company has seen an 80% decline in shares since the first Elevidys-related death was reported in March [5] Group 3: Sales Performance and Forecast - Sarepta expects Elevidys infusion volumes to be flat to slightly lower in Q4 due to disruptions this year, with third-quarter sales of Elevidys at $131.5 million, down from $281.9 million in the previous quarter [6]